✦ LIBER ✦

Pretreatment HBeAg level and an early decrease in HBeAg level predict virologic response to entecavir treatment for HBeAg-positive chronic hepatitis B

✍ Scribed by J. H. Kwon; J. W. Jang; S. Lee; J. Lee; K. W. Chung; Y. S. Lee; J. Y. Choi

Book ID: 108886645
Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 221 KB
Volume: 19
Category: Article
ISSN: 1352-0504
DOI: 10.1111/j.1365-2893.2011.01509.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Early on-treatment prediction of respons

Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels

✍ Vincent Rijckborst; Bettina E. Hansen; Yilmaz Cakaloglu; Peter Ferenci; Fehmi Ta 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 189 KB 👁 2 views

Ferenci is a consultant for, advises, is on the speakers' bureau of, and received grants from Roche. Dr. Janssen is a consultant for and received grants from Roche, Bristol-Myers Squibb, Schering-Plough, Novartis, and Gilead. Dr. Flisiak received grants from Roche.

Early serum HBsAg level as a strong pred

Early serum HBsAg level as a strong predictor of sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B

✍ C.-Y. Peng; H.-C. Lai; Y.-F. Li; W.-P. Su; P.-H. Chuang; J.-T. Kao 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 274 KB